Inventor · disambiguated record
Nuria A. Tamayo
Also filed as: TAMAYO NURIA · TAMAYO NURIA A
30 granted patents·16 pending applications·328 citations·filing 2002–2025
96Inventor score
Top patents by PatentIndex Score
46 records- 0198US11905281B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2020·Granted Feb 20, 2024·13 cites·16 claims
- 0298US11766436B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2021·Granted Sep 26, 2023·11 cites·19 claims
- 0398US11090304B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2019·Granted Aug 17, 2021·33 cites·3 claims
- 0498US10519146B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2018·Granted Dec 31, 2019·81 cites·33 claims
- 0596US12083121B2Substituted piperazines as KRAS G12C inhibitorsAMGEN INC·Filed 2022·Granted Sep 10, 2024·7 cites·5 claims
- 0696US11285156B2Substituted piperazines as KRAS G12C inhibitorsAMGEN INC·Filed 2019·Granted Mar 29, 2022·16 cites·4 claims
- 0794US7820665B2Imidazopyridazine inhibitors of PI3 kinase for cancer treatmentAMGEN INC·Filed 2008·Granted Oct 26, 2010·38 cites·9 claims
- 0893US12440491B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2023·Granted Oct 14, 2025·1 cites·4 claims
- 0992US7928140B2Benzothiazole PI3 kinase modulators for cancer treatmentAMGEN INC·Filed 2008·Granted Apr 19, 2011·32 cites·17 claims
- 1092US7115607B2Substituted piperazinyl amides and methods of useAMGEN INC·Filed 2002·Granted Oct 3, 2006·42 cites·14 claims
- 1189US12054476B2KIF18A inhibitorsAMGEN INC·Filed 2021·Granted Aug 6, 2024·1 cites·31 claims
- 1288US2025381187A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2025·Application pending·0 cites
- 1387US11236069B2KIF18A inhibitorsAMGEN INC·Filed 2019·Granted Feb 1, 2022·4 cites·25 claims
- 1485US12509442B2KIF18A inhibitorsAMGEN INC·Filed 2024·Granted Dec 30, 2025·0 cites·32 claims
- 1585US6977264B2Substituted piperidines and methods of useAMGEN INC·Filed 2002·Granted Dec 20, 2005·26 cites·19 claims
- 1684US11845760B2PRMT5 inhibitorsAMGEN INC·Filed 2021·Granted Dec 19, 2023·1 cites·46 claims
- 1784US2024174660A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2023·Application pending·0 cites
- 1880US8772480B2Inhibitors of PI3 kinase and/or mTORAMGEN INC·Filed 2012·Granted Jul 8, 2014·5 cites·25 claims
- 1978US7301022B2Vanilloid receptor ligands and their use in treatmentsAMGEN INC·Filed 2006·Granted Nov 27, 2007·4 cites·11 claims
- 2077US8729074B2Inhibitors of PI3 kinaseBO YUNXIN Y·Filed 2010·Granted May 20, 2014·5 cites·2 claims
- 2175US12459932B2KIF18A inhibitorsAMGEN INC·Filed 2019·Granted Nov 4, 2025·1 cites·34 claims
- 2275US12441736B2KIF18A inhibitorsAMGEN INC·Filed 2019·Granted Oct 14, 2025·1 cites·31 claims
- 2374US7504403B2Substituted heterocyclic compounds and methods of useAMGEN INC·Filed 2005·Granted Mar 17, 2009·2 cites·17 claims
- 2473US9296734B2Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2014·Granted Mar 29, 2016·2 cites·39 claims
- 2570US8415376B2Inhibitors of PI3 kinaseBO YUNXIN Y·Filed 2009·Granted Apr 9, 2013·1 cites·9 claims
- 2670US2020055845A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2019·Application pending·0 cites
- 2769US2024092794A1Novel prmt5 inhibitorsAMGEN INC·Filed 2023·Application pending·0 cites
- 2863US2019375749A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2019·Application pending·0 cites
- 2959US7026326B2Substituted heterocyclic compounds and methods of useAMGEN INC·Filed 2003·Granted Apr 11, 2006·1 cites·8 claims
- 3056US2023406860A1Heterocyclic spiro compounds and methods of useAMGEN INC·Filed 2021·Application pending·0 cites
- 3155US2024059703A1Heterocyclic spiro compounds and methods of useAMGEN INC·Filed 2021·Application pending·0 cites
- 3252US12435058B2KIF18A inhibitorsAMGEN INC·Filed 2020·Granted Oct 7, 2025·0 cites·21 claims
- 3352US2023159510A1Novel prmt5 inhibitorsAMGEN INC·Filed 2021·Application pending·0 cites
- 3452US2024101570A1Tricyclic carboxamide derivatives as prmt5 inhibitorsAMGEN INC·Filed 2021·Application pending·0 cites
- 3551US2022289724A1Kif18a inhibitorsAMGEN INC·Filed 2020·Application pending·0 cites
- 3651US2022281843A1Kif18a inhibitorsAMGEN INC·Filed 2020·Application pending·0 cites
- 3750US2009082358A1Vanilloid receptor ligands and their use in treatmentsNISHIMURA NOBUKO·Filed 2008·Application pending·0 cites
- 3848US12441705B2KIF18A inhibitorsAMGEN INC·Filed 2019·Granted Oct 14, 2025·0 cites·34 claims
- 3944US2006161001A1Substituted heterocyclic compounds and methods of useAMGEN INC·Filed 2005·Application pending·0 cites
- 4044US2006241296A1Vanilloid receptor ligands and their use in treatmentsDOHERTY ELIZABETH M·Filed 2006·Application pending·0 cites
- 4144US2006069110A1Substituted heterocyclic compounds and methods of useANDERSEN DENISE L·Filed 2005·Application pending·0 cites
- 4243US9309263B2Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereofAMGEN INC·Filed 2014·Granted Apr 12, 2016·0 cites·31 claims
- 4343US8476297B2TRP-M8 receptor ligands and their use in treatmentsNORMAN MARK H·Filed 2008·Granted Jul 2, 2013·0 cites·11 claims
- 4442US9394297B2Amides as pim inhibitorsAMGEN INC·Filed 2013·Granted Jul 19, 2016·0 cites·20 claims
- 4541US2004254178A1Substituted heterocyclic compounds and methods of useAMGEN INC·Filed 2004·Application pending·0 cites
- 4630US8431563B2Compounds that interact with glucokinase regulatory protein for the treatment of diabetesASHTON KATE·Filed 2011·Granted Apr 30, 2013·0 cites·34 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →